CN106029099A - 用于治疗细胞增殖性疾病的alk抑制剂与cdk抑制剂的组合 - Google Patents

用于治疗细胞增殖性疾病的alk抑制剂与cdk抑制剂的组合 Download PDF

Info

Publication number
CN106029099A
CN106029099A CN201480059490.0A CN201480059490A CN106029099A CN 106029099 A CN106029099 A CN 106029099A CN 201480059490 A CN201480059490 A CN 201480059490A CN 106029099 A CN106029099 A CN 106029099A
Authority
CN
China
Prior art keywords
compound
combination
cancer
alk
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480059490.0A
Other languages
English (en)
Chinese (zh)
Inventor
J·L·哈里斯
N·李
T·R·史密斯
Y·莫斯
A·伍德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN106029099A publication Critical patent/CN106029099A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201480059490.0A 2013-08-28 2014-08-28 用于治疗细胞增殖性疾病的alk抑制剂与cdk抑制剂的组合 Pending CN106029099A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361871275P 2013-08-28 2013-08-28
US61/871,275 2013-08-28
PCT/US2014/053244 WO2015031666A1 (en) 2013-08-28 2014-08-28 Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases

Publications (1)

Publication Number Publication Date
CN106029099A true CN106029099A (zh) 2016-10-12

Family

ID=51541330

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480059490.0A Pending CN106029099A (zh) 2013-08-28 2014-08-28 用于治疗细胞增殖性疾病的alk抑制剂与cdk抑制剂的组合

Country Status (12)

Country Link
US (2) US20160361314A1 (enExample)
EP (1) EP3038652B1 (enExample)
JP (1) JP6479812B2 (enExample)
KR (1) KR20160047521A (enExample)
CN (1) CN106029099A (enExample)
AU (3) AU2014312261A1 (enExample)
BR (1) BR112016004358A8 (enExample)
CA (1) CA2922684A1 (enExample)
ES (1) ES2674361T3 (enExample)
MX (1) MX2016002580A (enExample)
RU (1) RU2016110874A (enExample)
WO (1) WO2015031666A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016167511A2 (ko) * 2015-04-14 2016-10-20 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
KR101772134B1 (ko) 2015-04-14 2017-08-29 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US11208630B2 (en) * 2015-12-24 2021-12-28 University Of Florida Research Foundation, Incorporated AAV production using suspension adapted cells
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
WO2019136451A1 (en) 2018-01-08 2019-07-11 G1 Therapeutics, Inc. G1t38 superior dosage regimes
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CA3130706A1 (en) * 2019-04-04 2020-10-08 Dana-Farber Cancer Institute, Inc. Cdk2/5 degraders and uses thereof
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
TW202131917A (zh) 2019-11-18 2021-09-01 日商中外製藥股份有限公司 併用醫藥
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230117684A1 (en) * 2020-03-05 2023-04-20 Pfizer Inc. Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
CN116261455B (zh) * 2020-09-25 2024-11-01 苏州亚盛药业有限公司 一种药物组合物及其在治疗癌症中的用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101616895A (zh) * 2006-12-08 2009-12-30 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
WO2010132725A2 (en) * 2009-05-13 2010-11-18 The University Of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
CN102186856A (zh) * 2008-08-22 2011-09-14 诺瓦提斯公司 作为cdk抑制剂的吡咯并嘧啶化合物
WO2012106540A1 (en) * 2011-02-02 2012-08-09 Irm Llc Methods of using alk inhibitors
CN102869358A (zh) * 2010-04-13 2013-01-09 诺华有限公司 用于治疗癌症的包含细胞周期蛋白依赖性激酶4或细胞周期蛋白依赖性激酶6(CDK4/6)抑制剂和mTOR抑制剂的组合

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101149295B1 (ko) * 2006-12-08 2012-07-05 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101616895A (zh) * 2006-12-08 2009-12-30 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
CN102186856A (zh) * 2008-08-22 2011-09-14 诺瓦提斯公司 作为cdk抑制剂的吡咯并嘧啶化合物
WO2010132725A2 (en) * 2009-05-13 2010-11-18 The University Of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
CN102869358A (zh) * 2010-04-13 2013-01-09 诺华有限公司 用于治疗癌症的包含细胞周期蛋白依赖性激酶4或细胞周期蛋白依赖性激酶6(CDK4/6)抑制剂和mTOR抑制剂的组合
WO2012106540A1 (en) * 2011-02-02 2012-08-09 Irm Llc Methods of using alk inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
P.BONVINI等: "The effect of the cyclin-dependent kinase inhibitor flavopitidol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity", 《HAEMATOLOGICA》 *
ROBERT ROSKOSKI JR.: "Anaplastic lymphoma kinase(ALK):Structure, oncogenic activation, and pharmacological inhibition", 《PHARMACOLOGICAL RESEARCH》 *
THOMAS H.MARSILJE等: "Synthesis, Structure−Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK)Inhibitor", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
刘昌发: "《药理学》", 31 July 2007, 郑州：河南科学技术出版社 *
李向荣: "《药剂学》", 28 February 2010, 浙江大学出版社 *

Also Published As

Publication number Publication date
CA2922684A1 (en) 2015-03-05
AU2018236813A1 (en) 2018-10-18
ES2674361T3 (es) 2018-06-29
JP6479812B2 (ja) 2019-03-06
US20160361314A1 (en) 2016-12-15
WO2015031666A1 (en) 2015-03-05
BR112016004358A8 (pt) 2020-02-11
RU2016110874A (ru) 2017-10-04
US20180318305A1 (en) 2018-11-08
MX2016002580A (es) 2016-10-26
RU2016110874A3 (enExample) 2018-06-27
JP2016529285A (ja) 2016-09-23
AU2017219093A1 (en) 2017-09-14
EP3038652A1 (en) 2016-07-06
AU2014312261A1 (en) 2016-03-10
EP3038652B1 (en) 2018-03-21
KR20160047521A (ko) 2016-05-02

Similar Documents

Publication Publication Date Title
CN106029099A (zh) 用于治疗细胞增殖性疾病的alk抑制剂与cdk抑制剂的组合
AU2019204938B2 (en) Mdm2 inhibitors and combinations thereof
JP6532878B2 (ja) 組合せ医薬
US8247397B2 (en) Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
AU2013295771B2 (en) Pharmaceutical combinations of a CDK4/6 inhibitor and a B-Raf inhibitor
KR20150036014A (ko) 위장 기질 종양을 치료하는 방법
KR20160020502A (ko) 제약 조합물
JP2013507442A (ja) 組合せ
CN121059617A (zh) 包含Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂的组合产品及其用途
JP2023075161A (ja) 癌の処置
KR20160090814A (ko) Jak, cdk 및 pim의 억제제를 포함하는 조합 요법
US20180318275A1 (en) Combination therapy using pi3k inhibitor and mdm2 inhibitor
KR20180037975A (ko) 포도막 흑색종을 치료하기 위한 mdm2 억제제
CN112237579B (zh) 药物组合及其用途
CN108135905A (zh) 用于治疗癌症的cdk4/6抑制剂lee011、mek1/2抑制剂曲美替尼以及可任选还包括pi3k抑制剂byl719的组合
TW202313056A (zh) 包含ＰＩ３Ｋα抑制劑的藥物組合
Lapidus et al. Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice
WO2016025656A1 (en) Combinations of an erk inhibitor and a pi3k inhibitor or dual pi3k/tor inhibitor and related methods
HK1248605A1 (en) Mdm2 inhibitors and combinations thereof
HK1248605B (en) Mdm2 inhibitors and combinations thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20191022